Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model-Reference-Cited by-同舟云学术

Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model

Published:2015-06-25 Issue:2 Volume:41 Page:598-610
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Ghoshal A,Rook J M,Dickerson J W,Roop G N,Morrison R D,Jalan-Sakrikar N,Lamsal A,Noetzel M J,Poslusney M S,Wood M R,Melancon B J,Stauffer S R,Xiang Z,Daniels J S,Niswender C M,Jones C K,Lindsley C W,Conn P J

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/npp2015189.pdf

Reference55 articles.

1. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM et al (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nature Neurosci 6: 51–58.

2. Barak S, Weiner I (2011). The M(1)/M(4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol 14: 1233–1246.

3. Bekinschtein P, Weisstaub N (2014). Role of PFC during retrieval of recognition memory in rodents. J Physiol Paris 108: 252–255.

4. Berman JA, Talmage DA, Role LW (2007). Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol 78: 193–223.

5. Brigman JL, Ihne J, Saksida LM, Bussey TJ, Holmes A (2009). Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL/6J mice. Front Behav Neurosci 3: 2.

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials;Schizophrenia Research;2024-12

2. Neonatal anesthesia with remimazolam Reduces the expression of synaptic proteins and increases depressive behavior in adult mice;Neuroscience Letters;2024-09

3. A golden age of muscarinic acetylcholine receptor modulation in neurological diseases;Nature Reviews Drug Discovery;2024-08-14

4. Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment;Clinical Drug Investigation;2024-06-21

5. Novel α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor (AMPAR) potentiator LT‐102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia;CNS Neuroscience & Therapeutics;2024-04